AR036793A1 - Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante - Google Patents
Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvanteInfo
- Publication number
- AR036793A1 AR036793A1 ARP020103816A ARP020103816A AR036793A1 AR 036793 A1 AR036793 A1 AR 036793A1 AR P020103816 A ARP020103816 A AR P020103816A AR P020103816 A ARP020103816 A AR P020103816A AR 036793 A1 AR036793 A1 AR 036793A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- tumor antigen
- vaccines
- adjutive
- cytokin
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title abstract 3
- 229940023146 nucleic acid vaccine Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108010041986 DNA Vaccines Proteins 0.000 abstract 1
- 229940021995 DNA vaccine Drugs 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960004854 viral vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se presentan vacunas de ácido nucleico que comprenden por lo menos un ácido nucleico que codifica un antígeno tumoral y por lo menos un ácido nucleico que codifica citoquina adyuvante para la profilaxis o tratamiento de tumores. Las vacunas virales se combinan optativamente o se administran además con un refuerzo de vacuna de virus recombinante o ADN. Reivindicación 1: Una vacuna de ácido nucleico que comprende (a) por lo menos un polinucleótido que codifica por lo menos una porción antigénica de por lo menos una secuencia de aminoácidos que comprende o es codificada por al menos una de las SEC.ID.NOS: 1-47 o variantes de las mismas, o una secuencia de ácido nucleico complementaria de las mismas y (b) por lo menos un polinucleótido que codifica por lo menos una porción codificadora adyuvante de por lo menos una secuencia de aminoácidos que comprende o es codificada por al menos una de las SEC.ID.NOS: 60-77 o variantes de las mismas, o una secuencia complementaria de las mismas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32837101P | 2001-10-10 | 2001-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036793A1 true AR036793A1 (es) | 2004-10-06 |
Family
ID=23280723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103816A AR036793A1 (es) | 2001-10-10 | 2002-10-10 | Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050261213A1 (es) |
| EP (1) | EP1507540A4 (es) |
| AR (1) | AR036793A1 (es) |
| AU (1) | AU2002326961A1 (es) |
| BR (1) | BR0206112A (es) |
| NO (1) | NO20032586L (es) |
| WO (1) | WO2003031569A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) * | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| WO2004099389A2 (en) * | 2003-03-24 | 2004-11-18 | The Scripps Research Institute | Dna vaccines against tumor growth and methods of use thereof |
| JP5285855B2 (ja) | 2003-11-12 | 2013-09-11 | アメリカ合衆国 | 膵癌を処置および予防するためのカスタムベクター |
| EP1694364B1 (en) * | 2003-11-12 | 2014-04-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | System for treating and preventing breast cancer |
| SI1839120T1 (sl) | 2004-12-21 | 2013-12-31 | Janssen Biotech, Inc. | Vektorji na osnovi protitelesa anti-il-12, gostiteljske celice in postopki proizvodnje ter uporabe |
| JP2008528623A (ja) * | 2005-01-28 | 2008-07-31 | ラモット アット テル アビブ ユニバーシティ， リミテッド | 抗ＭＵＣ１のα／β抗体 |
| ES2715890T3 (es) * | 2013-11-01 | 2019-06-06 | Pfizer | Vectores de expresión de antígenos asociados a la próstata |
| SG11201810631SA (en) * | 2016-06-03 | 2018-12-28 | Etubics Corp | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| JP7287611B2 (ja) * | 2018-02-07 | 2023-06-06 | 学校法人日本医科大学 | 改良型アデノ随伴ウイルスベクター |
| CN108624691A (zh) * | 2018-06-22 | 2018-10-09 | 杭州西合精准医疗科技有限公司 | 一种用于判断前列腺疾病的标志物及其应用 |
| US12029778B2 (en) | 2019-05-13 | 2024-07-09 | Yale University | Interleukin-18 mimics and methods of use |
| WO2022051232A1 (en) * | 2020-09-02 | 2022-03-10 | 4D Molecular Therapeutics Inc. | Codon optimized rpgrorf 15 genes and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013268A (en) * | 1994-04-22 | 2000-01-11 | Corixa Corporation | Methods for enhancement of protective immune responses |
| DE19648625A1 (de) * | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| JP4024366B2 (ja) * | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | ポリペプチド |
| WO1999061068A1 (en) * | 1998-05-29 | 1999-12-02 | The Trustees Of The University Of Pennsylvania | Anti-prostate cancer vaccines, and methods of making, using and evaluating the same |
| US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
| US6495130B1 (en) * | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| AU2002239441A1 (en) * | 2000-11-01 | 2002-05-27 | American Foundation For Biological Research, Inc. | Methods and compositions for inducing cell-mediated immune responses |
-
2002
- 2002-09-18 WO PCT/US2002/029640 patent/WO2003031569A2/en not_active Application Discontinuation
- 2002-09-18 EP EP02761720A patent/EP1507540A4/en not_active Withdrawn
- 2002-09-18 AU AU2002326961A patent/AU2002326961A1/en not_active Abandoned
- 2002-09-18 BR BR0206112-0A patent/BR0206112A/pt not_active Application Discontinuation
- 2002-10-10 AR ARP020103816A patent/AR036793A1/es unknown
-
2003
- 2003-03-28 US US10/401,386 patent/US20050261213A1/en not_active Abandoned
- 2003-06-06 NO NO20032586A patent/NO20032586L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1507540A4 (en) | 2006-12-06 |
| US20050261213A1 (en) | 2005-11-24 |
| WO2003031569A2 (en) | 2003-04-17 |
| AU2002326961A1 (en) | 2003-04-22 |
| NO20032586D0 (no) | 2003-06-06 |
| WO2003031569A3 (en) | 2004-12-29 |
| EP1507540A2 (en) | 2005-02-23 |
| NO20032586L (no) | 2003-08-04 |
| BR0206112A (pt) | 2005-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036793A1 (es) | Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante | |
| ATE292685T1 (de) | Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe | |
| PT1090033E (pt) | Particulas de proteinas de envelope do hcv: utilizacao para vacinacao | |
| EP0280710A4 (en) | DNA ENCODING THE T CELL SURFACE PROTEIN T4 AND USE OF T4 FRAGMENTS IN THE TREATMENT OF AIDS. | |
| CA2617341A1 (en) | Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus | |
| JP2002542827A5 (es) | ||
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| WO2002022686A3 (en) | Defensin-antigen fusion proteins | |
| NO944245L (no) | Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner | |
| CO5580165A1 (es) | Vacunas de rotavirus modificado | |
| ES2039239T3 (es) | Vacuna contra el virus varicela-zoster. | |
| MX2022001028A (es) | Vacuna de la fiebre porcina africana. | |
| JP2003530088A5 (es) | ||
| DE60228136D1 (de) | Cytokin-proteinfamilie | |
| RU2007106900A (ru) | Иммуногенные комплексы, способ их приготовления и их применение в фармацевтических композициях | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| AU6683400A (en) | Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat | |
| PE20001287A1 (es) | Composicion farmaceutica que contiene fragmentos de adn codificador de una proteina antigenica con efecto antitumoral | |
| WO2003095480A3 (en) | Brachyspira hyodysenteriae vaccine | |
| NZ237532A (en) | Gp75, nucleic acid encoding it, fragments and vaccines | |
| WO2002022687A3 (en) | Viral chemokine-tumur antigen fusion proteins | |
| FI113621B (fi) | Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi | |
| ES2058116T3 (es) | El virus varicella-zoster como una vacuna recombinante viva. | |
| FI953371A (fi) | TBE-virusinfektiota vastaan tähtäävään immunisointiin tarkoitetut parannetut rokotteet sekä menetelmä niiden valmistamiseksi | |
| WO2002038769A3 (de) | Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |